Traditionally, only a small fraction of oncology drugs make it from phase 1 to commercialization. And biopharmaceutical companies continue to face significant challenges in understanding how new oncology drug approvals affect treatment patterns and market share. To deal with such hurdles, Oracle has recently launched CancerMPact Treatment Architecture Trends (PDF overview here), a resource that…